Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1507-1510

  Kline, T ^a   Trent, M S ^b   Stead, C M ^b   Lee, M S ^c   Sousa, M C ^c   Felise, H B ^a   Nguyen, H V ^a   Miller, S I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

4 Deoxy 4 substituted arabinose analogs; Aminoarabinose; Lipid A remodeling; Polymyxin resistance

Indexed keywords

ARABINOSE DERIVATIVE; LIPID A; POLYMYXIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SCREENING; DRUG SYNTHESIS; NONHUMAN; OUTER MEMBRANE;

ANTI-BACTERIAL AGENTS; ARABINOSE; AZIDES; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; HEXOSYLTRANSFERASES; LIPID A; POLYMYXINS;

BACTERIA (MICROORGANISMS);

EID: 38949175780     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.061     Document Type: Article

References (25)

1. Beringer P. Curr. Opin. Pulm. Med. 7 (2001) 434
2. Brogden K.A. Nat. Rev. Microbiol. 3 (2005) 238
3. Peschel A. Trends Microbiol. 10 (2002) 179
4. McPhee J.B., Lewenza S., and Hancock R.E. Mol. Microbiol. 50 (2003) 205
5. Bader M.W., Navarre W.W., Shiau W., Nikaido H., Frye J.G., McClelland M., Fang F.C., and Miller S.I. Mol. Microbiol. 50 (2003) 219
6. Trent M.S., Ribeiro A.A., Lin S., Cotter R.J., and Raetz C.R. J. Biol. Chem. 276 (2001) 43122
7. Baron C., and Coombes B. Infect. Disord. Drug Targets 7 (2007) 19
8. Breazeale S.D., Ribeiro A.A., McClerren A.L., and Raetz C.R. J. Biol. Chem. 280 (2005) 14154
9. Williams G.J., Breazeale S.D., Raetz C.R., and Naismith J.H. J. Biol. Chem. 280 (2005) 23000
10. Naleway J.J., Raetz C.R., and Anderson L. Carbohydr. Res. 179 (1988) 199
11. Takeo K., Murata Y., and Kitamura S. Carbohydr. Res. 224 (1992) 311
12. Upreti M.R.D., and Vishwakarma R.A. Tetrahedron 56 (2000) 6577
13. Takaya K., Nagahori N., Kurogochi M., Furuike T., Miura N., Monde K., Lee Y.C., and Nishimura S. J. Med. Chem. 48 (2005) 6054
14. For the synthesis of compound 2 and analytical data, please see Supplementary information.
15. Wittmann V., and Wong C.H. J. Org. Chem. 62 (1997) 2144
16. For the synthesis of compound 4 and analytical data, please see Supplementary information.
17. Abrunhosa-Thomas I., Ribiere P., and Adcock A.C. Synthesis (2006) 325
18. Deprele S.M., and Jean-Luc A. J. Organiomet. Chem. 634-644 (2002) 154
19. For the synthesis of compound 11 and analytical data, please see Supplementary information. Compound 11.
20. Gatzeva-Topalova P.Z., May A.P., and Sousa M.C. Biochemistry 44 (2005) 5328
21. Gatzeva-Topalova P.Z., May A.P., and Sousa M.C. Structure 13 (2005) 929
22. Gatzeva-Topalova P.Z., May A.P., and Sousa M.C. Biochemistry 43 (2004) 13370
23. Gunn J.S., Ryan S.S., Van Velkinburgh J.C., Ernst R.K., and Miller S.I. Infect. Immun. 68 (2000) 6139
24. TLC plates were exposed overnight to a PhosphorImager Screen and product formation detected using a Bio-Rad Molecular Imager PhosphorImager. Enzyme activity was calculated by determining the percentage of the substrate converted to product by densitometry using Quantity One Software.
25. A preliminary assay against whole bacteria showed that none of the compounds, at highest concentrations ranging from 90 mM (compound 1) to 500 mM (compound 7), were able to restore susceptibility to the CAP polymyxin in Salmonella strain JSG435 that constitutively synthesizes a lipid A modified with aminoarabinose. The lack of effect against intact bacteria could result from insufficient activity against the target, poor permeability/retention, metabolic inactivation, or a combination of these factors.